Metrics as of 10/17/2026, 07:38 AM (Berlin time), refresh in progress.
Eli Lilly and Company Stock
Eli Lilly and Company
Company data
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- Country
- United States
- CEO
- David A. Ricks
- Employees
- 50,000
- Market cap
- $1.18 T
- IPO
- 01/06/1972
Eli Lilly and Company is a prominent global pharmaceutical firm in the Healthcare sector, headquartered in Indianapolis, USA. Established in 1876, the company employs approximately 50,000 people. Its business model focuses on the research, development, and commercialization of human medicines worldwide. The…
Company description based on the data provider's company data, AI-assisted, created on 15/10/2026. Not investment advice.
Eli Lilly and Company stock: price history
1D
+0.4%
1W
+6.6%
1M
+10.5%
6M
+35.6%
YTD
+17.0%
1Y
+53.4%
2Y
+37.2%
5Y
+428.4%
10Y
+1,485.8%
Next earnings date
Next earnings date
29/10/2026 (in 12 days)
Volatility around earnings
~90% stronger price swings than usual
Pattern chart
Pattern detected by the Market Jury detector vsqueeze-release-v1.0 on 14/10/26. Not a buy or sell signal.Beta
What does this mean?
Volatility squeeze
BullishPrice swings had compressed unusually tight beforehand (volatility near a low) and are now releasing into a stronger move. Technical analysis views such tight phases as often preceding a bigger move.
Chart patterns are a purely technical signal derived from price action. At Market Jury they do not feed into the agents' buy or sell decisions, they are supplementary information only.
Eli Lilly and Company stock scores
- Valuation
Visible after free registration
- Trend
Visible after free registration
- Quality
Visible after free registration
- Dividend
Visible after free registration
- Growth
Visible after free registration
- Insider
Visible after free registration
- Earnings
Visible after free registration
- Revisions
Visible after free registration
- Sentiment
Visible after free registration
- Short Pressure
Visible after free registration
Register for free
Unlock all 11 scores
- 5 credits free on registration
- Access to virtual portfolios and watchlist
- No credit card, no payment details needed
- No subscription, no minimum term
- Our own servers in Germany, no US cloud
Deterministically calculated from financial metrics, not investment advice. Updated nightly, last on 17/10/2026.
Business model & megatrends
Robust business model that benefits noticeably from at least one megatrend.
Eli Lilly and Company is a globally operating pharmaceutical company specializing in the research, development, and marketing of human pharmaceuticals. Its product portfolio encompasses therapeutics for a broad range of indications, including diabetes (particularly insulin preparations), oncology, immunology, and neurological diseases such as schizophrenia and migraine. The majority of revenues are generated through the sale of pharmaceuticals, while collaborations with various partners play a supplementary role. The business model is primarily characterized by highly specialized research and patent-protected medications.
- Revenue model
- Transactional
- Recurring revenue
- High
- Pricing power
- Strong
- Moat
- None
- Moat type
- None
- Capital intensity
- High
- Customer concentration
- Unknown
Suppliers & customers in our universe
Incyte CorporationDescription
AbCellera Biologics Inc.DescriptionAsk the agents about Eli Lilly and Company
Analyst assessment of Eli Lilly and Company
PRICE TARGET LOW
US$940.00
CONSENSUS
US$1,345.80
MEDIAN
US$1,376.00
PRICE TARGET HIGH
US$1,500.00
0
STRONG BUY
33
BUY
9
HOLD
3
SELL
0
STRONG SELL
45
TOTAL · Buy
As of: 12/10/2026
Eli Lilly and Company stock metrics
P/E
42.06
P/B
33.11
EV/EBITDA
28.39
RETURN ON EQUITY
20.9%
NET MARGIN
30.9%
DEBT/EQUITY
1.62
DIVIDEND YIELD
0.5%
AS OF
30/06/2026
Free float & liquidity
FREE FLOAT
90.1%
FLOAT SHARES
848,416,823
AVG. DAILY VOLUME (30D)
2,282,743
Insider transactions (SEC)
Alvarez Ralph
Sulzberger Gabrielle
LUCIANO JUAN R
Fyrwald J Erik
Seymour Melissa
Attention
3 mentions today in US forums, 67% fewer than yesterdayPrice since yesterday: +0.4%
Forums (Reddit)
See the full forum history with Pro.
Institutional holders
Dividends & Stock splits
Dividends
Stock splits
Smart Money
Register for free
Register now to see which funds are invested
- 5 credits free on registration
- Access to virtual portfolios and watchlist
- No credit card, no payment details needed
- No subscription, no minimum term
- Our own servers in Germany, no US cloud
Comparable stocks
Frequently asked questions about Eli Lilly and Company stock
What does Eli Lilly and Company do?
Eli Lilly and Company is a company in the Healthcare sector, Drug Manufacturers - General industry, headquartered in United States.
The CEO is David A. Ricks, the company employs around 50,000 people.
The IPO was on 01/06/1972; the stock trades on NYSE under the ticker LLY.
What do analysts say about Eli Lilly and Company stock?
45 analysts rate the stock, the consensus is Buy (as of 12/10/2026).
The average price target is US$1,345.80, ranging from US$940.00 to US$1,500.00, with a median of US$1,376.00.
This is an external assessment, not a statement by Market Jury.
When does Eli Lilly and Company report next?
The next earnings date is 29/10/2026.
Around past earnings, price swings were roughly 90% stronger than usual.
Does Eli Lilly and Company pay a dividend?
Yes. The last dividend was US$1.73 per share, ex-date 14/08/2026, paid on 10/09/2026.
The dividend yield is 0.5% (as of 30/06/2026).
Which stocks are comparable to Eli Lilly and Company?
Comparable stocks include Johnson & Johnson, AbbVie, Merck &, Amgen, Gilead Sciences, Pfizer, Bristol-Myers Squibb Company and Biogen.
How can I get Eli Lilly and Company stock analyzed?
Clicking "Analyze stock" lets five strategies assess Eli Lilly and Company against fixed, published rules and judge it bullish, neutral or bearish. The jury states where it disagrees. A free account starts with 5 credits, a quick check costs 1 credit, a full analysis 2 credits.
Not investment advice. Past performance is not an indicator of future results.